Clinical Trial Update: Lcr35® for Bacterial Vaginosis Prevention [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Lcr35 probiotic for preventing bacterial vaginosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Vaginosis

Drugs mentioned

• Lcr35 (Lactobacillus rhamnosus GG (Lcr35 strain))

Snippet

Sponsor: Laboratoires Lyocentre | Conditions: Bacterial Vaginosis | Phase 3 | Status: COMPLETED